Abstract
The pathogenesis of inflammatory bowel syndrome (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC) is poorly understood. However, an inflammatory component is a common hallmark. It has been suggested that CD principally involves Th1 and/or Th17 cells, while UC is considered to be more Th2 driven. Because vasoactive intestinal peptide (VIP) has emerged in the last decade as a putative candidate for the treatment of inflammatory diseases with a Th1 component, it may as well serve as a therapeutic target in CD. In addition, experiments using mice deficient in VIP or its receptors have revealed that the endogenously-produced VIP may participate in the regulation of immunity. The aim of the present review is to summarize the quite considerable array of data which suggests that the VIP-receptor system plays a key role in modulating multiple molecular and cellular players involved in IBD.
Keywords: Crohn’s disease, IBD, inflammation, neuroimmunomodulation, neuropeptide, VIP, Autoimmune diseases, ulcerative colitis (UC), predominant anti-inflammatory action, neuroimmunopeptide, pituitary adenylate cyclaseactivating polypeptide (PACAP), airflow obstruction, airway inflammation.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:VIP in Inflammatory Bowel Disease: State of the Art
Volume: 12 Issue: 4
Author(s): Catalina Abad, Rosa Gomariz, James Waschek, Javier Leceta, Carmen Martinez, Yasmina Juarranz and Alicia Arranz
Affiliation:
Keywords: Crohn’s disease, IBD, inflammation, neuroimmunomodulation, neuropeptide, VIP, Autoimmune diseases, ulcerative colitis (UC), predominant anti-inflammatory action, neuroimmunopeptide, pituitary adenylate cyclaseactivating polypeptide (PACAP), airflow obstruction, airway inflammation.
Abstract: The pathogenesis of inflammatory bowel syndrome (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC) is poorly understood. However, an inflammatory component is a common hallmark. It has been suggested that CD principally involves Th1 and/or Th17 cells, while UC is considered to be more Th2 driven. Because vasoactive intestinal peptide (VIP) has emerged in the last decade as a putative candidate for the treatment of inflammatory diseases with a Th1 component, it may as well serve as a therapeutic target in CD. In addition, experiments using mice deficient in VIP or its receptors have revealed that the endogenously-produced VIP may participate in the regulation of immunity. The aim of the present review is to summarize the quite considerable array of data which suggests that the VIP-receptor system plays a key role in modulating multiple molecular and cellular players involved in IBD.
Export Options
About this article
Cite this article as:
Abad Catalina, Gomariz Rosa, Waschek James, Leceta Javier, Martinez Carmen, Juarranz Yasmina and Arranz Alicia, VIP in Inflammatory Bowel Disease: State of the Art, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/187153012803832576
DOI https://dx.doi.org/10.2174/187153012803832576 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Inhibition of Platelet Reactivity. Clinical and Pharmacodynamic Effects
Current Vascular Pharmacology Pharmacogenetic Modulation of Platelet Inhibition
Current Pharmacogenomics and Personalized Medicine Circulating Endothelial Progenitor Cells as Biomarkers for Prediction of Cardiovascular Outcomes
Current Medicinal Chemistry Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System
Current Pharmaceutical Design Coffee and Depression: A Short Review of Literature
Current Pharmaceutical Design Aortic Dissection: A Review of the Pathophysiology, Management and Prospective Advances
Current Cardiology Reviews Lipoprotein(a): Medical Treatment Options for an Elusive Molecule
Current Pharmaceutical Design Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews Psychological Stress in Pathogenesis of Essential Hypertension
Current Hypertension Reviews Importance of Receptor-targeted Systems in the Battle Against Atherosclerosis
Current Pharmaceutical Design A New Risk Chart of Acute Myocardial Infarction in Men by an Innovative Algorithm: A Pilot Study
Current Pharmacogenomics and Personalized Medicine Beclin 1 Biology and its Role in Heart Disease
Current Cardiology Reviews Computer-Aided Drug Design for AMP-Activated Protein Kinase Activators
Current Computer-Aided Drug Design Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Serum Vitamin D Concentration and Potential Risk Factors for its Deficiency in HIV Positive Individuals
Current HIV Research Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry Fetzima (levomilnacipran), a Drug for Major Depressive Disorder as a Dual Inhibitor for Human Serotonin Transporters and Beta-Site Amyloid Precursor Protein Cleaving Enzyme-1
CNS & Neurological Disorders - Drug Targets Novel Therapeutic Strategies for the Homozygous Familial Hypercholesterolemia
Recent Patents on Cardiovascular Drug Discovery Genetic Studies of Type 2 Diabetes in South Asians: A Systematic Overview
Current Diabetes Reviews